logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10111900 B1

PDFFull Text
Date of Patent:
Oct. 30, 2018

Filed:

Dec. 21, 2016

β-glucan methods and compositions that affect the tumor microenvironment

Applicant:

Biothera, Inc., Eagan, MN (US);

Inventors:

Nandita Bose, Plymouth, MN (US);

Keith Gorden, Woodbury, MN (US);

Anissa Sh. Chan, Arden Hills, MN (US);

Steven Leonardo, Rosemount, MN (US);

Jeremy Graff, Indianapolis, IN (US);

Xiaohong Qiu, Edina, MN (US);

Takashi Kangas, Shoreview, MN (US);

Kathryn A. Fraser, St. Paul, MN (US);

Adria Bykowski Jonas, Eden Prairie, MN (US);

Nadine Ottoson, Lakeville, MN (US);

Ross Fulton, St. Paul, MN (US);

Assignee:

BIOTHERA, INC., Eagan, MN (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Misook Yu

Assistant Examiner:

Kauser M Akhoon

Int. Cl.
CPC ...
A61K 31/716 (2006.01); A61K 31/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 5/0784 (2010.01); C12N 5/0786 (2010.01); C12N 5/0783 (2010.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/716 (2013.01); A61K 39/3955 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3053 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 5/0639 (2013.01); C12N 5/0645 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2500/34 (2013.01); C12N 2501/052 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/24 (2013.01); C12N 2501/51 (2013.01); C12N 2502/1114 (2013.01);
Abstract

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Find Patent Forward Citations

Loading…